Withdrawal of Alupent

The short-acting bronchodilator orciprenaline sulphate (Alupent) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA.

It concluded that the adverse events associated with the drug outweigh its clinical benefits.

Patients who are currently receiving Alupent should be switched to a more selective ß2-agonist, such as salbutamol or terbutaline, as soon as possible.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...